BioMarin Pharmaceutical Inc. (LON:0HNC)

Market Cap	8.32B
Revenue (ttm)	2.28B
Net Income (ttm)	405.48M
Shares Out	n/a
EPS (ttm)	2.09
PE Ratio	20.51
Forward PE	12.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	532
Average Volume	627
Open	58.35
Previous Close	59.22
Day's Range	58.08 - 59.87
52-Week Range	53.55 - 94.51
Beta	n/a
RSI	64.43
Earnings Date	Aug 1, 2025

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1996
• Employees: 3,040
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HNC

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD